LGALS3 Gene Expression for Allergic Asthma Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic approaches for asthma are hindered by the disease's heterogeneity, with a lack of specific biomarkers for nonallergic asthma and insufficient differentiation between allergic and nonallergic asthma types, leading to inadequate treatment responses.
Innovation Solution
An in vitro method assessing the expression levels of the LGALS3 gene and other biomarkers (TGFB1, ALOX5, BAX, CCL5, CD40, CHI3L1, CPA3, IL1R2, IL4R, PI3, RNASE3, SELL) in biological samples to diagnose and prognose allergic and nonallergic asthma, enabling differential diagnosis and personalized treatment strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic approaches are used for asthma, then general asthma diagnosis can be made, but specific differentiation between allergic and nonallergic asthma types cannot be achieved
Solution Approach 1:
The patent segments asthma diagnosis into distinct endotype categories (allergic asthma, nonallergic asthma, eosinophilic, neutrophilic, paucigranulocytic) by measuring expression levels of multiple specific genes (IL4R, IL13R, IL5R, GATA3, RORC, GCMC, SELL, CCR3, CXCR1, CXCR2, MPO, MBL2, LGALS3). This segmentation enables precise differentiation between asthma subtypes that conventional methods cannot distinguish.
Solution Approach 2:
The patent changes the diagnostic parameter from general clinical assessment to quantitative gene expression levels. By measuring the expression levels of specific genes associated with different inflammatory pathways and immune responses, the method transforms the diagnostic approach to provide molecular-level precision in distinguishing asthma endotypes.
2Adaptability or versatility
If conventional treatment approaches are used for asthma, then general symptom management can be provided, but personalized treatment for specific asthma endotypes cannot be achieved
Solution Approach 1:
The patent performs preliminary classification of asthma endotypes through gene expression analysis before initiating treatment. By identifying the specific asthma subtype (allergic, nonallergic, eosinophilic, neutrophilic, or paucigranulocytic) in advance, clinicians can select the most appropriate treatment strategy from the outset, improving treatment reliability and avoiding trial-and-error approaches.
Solution Approach 2:
The patent applies the principle of local quality by matching specific treatments to specific asthma endotypes. Each asthma subtype has tailored therapeutic recommendations based on its molecular characteristics, allowing for localized, precision medicine approaches rather than uniform treatment protocols for all asthma patients.
3Measurement precision
If general asthma classification is used, then broad treatment categories can be applied, but specific biomarker-guided therapy selection cannot be achieved
Solution Approach 1:
The patent employs a multi-functional gene expression panel that simultaneously serves multiple diagnostic purposes: differentiating allergic vs. nonallergic asthma, identifying eosinophilic vs. neutrophilic vs. paucigranulocytic phenotypes, and predicting treatment response. This universal approach consolidates multiple diagnostic functions into a single comprehensive assay, reducing overall diagnostic complexity while maintaining high precision.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention refers to the medical field. Particularly, the present invention refers to an in vitro method for the diagnosis of allergic asthma or nonallergic asthma in a subject suffering from asthma, or for the differential diagnosis of allergic asthma and nonallergic asthma in a subject suffering from asthma, or for the prognosis of asthma in a subject suffering from asthma, which comprises assessing the expression level of the LGALS3 gene in a biological sample obtained from the subject. It also refers to the in vitro use of the expression level of the LGALS3 gene, or in vitro use of a kit comprising reagents for the same purposes.